ProQR Therapeutics N.V.
$1.45+1.40%(+$0.02)
TickerSpark Score
49/100
80
Valuation
40
Profitability
10
Growth
84
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRQR research report →
52-Week Range7% of range
Low $1.33
Current $1.45
High $3.10
Companywww.proqr.com
ProQR Therapeutics N. V. , a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.
- CEO
- Daniel Anton de Boer
- IPO
- 2014
- Employees
- 166
- HQ
- Leiden, NL
Price Chart
-17.33% · this period
Valuation
- Market Cap
- $152.77M
- P/E
- -2.88
- P/S
- 9.78
- P/B
- 3.49
- EV/EBITDA
- -1.47
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.75%
- Op Margin
- -345.52%
- Net Margin
- -339.41%
- ROE
- -86.47%
- ROIC
- -67.64%
Growth & Income
- Revenue
- $15.28M · -19.18%
- Net Income
- $-40,519,110 · -45.95%
- EPS
- $-0.38 · -11.76%
- Op Income
- $-42,154,897
- FCF YoY
- -36.70%
Performance & Tape
- 52W High
- $3.10
- 52W Low
- $1.33
- 50D MA
- $1.68
- 200D MA
- $1.98
- Beta
- 0.07
- Avg Volume
- 555.70K
Get TickerSpark's AI analysis on PRQR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Valerio Domenico | other | 0 |
| Mar 18, 26 | Valerio Domenico | other | 0 |
| Mar 18, 26 | Valerio Domenico | other | 5,815 |
| Mar 18, 26 | Valerio Domenico | other | 32,164 |
| Mar 18, 26 | Valerio Domenico | other | 27,500 |
| Mar 18, 26 | Valerio Domenico | other | 14,918 |
| Mar 18, 26 | Valerio Domenico | other | 24,615 |
| Mar 18, 26 | Valerio Domenico | other | 23,239 |
| Mar 18, 26 | Valerio Domenico | other | 23,931 |
| Mar 18, 26 | Valerio Domenico | other | 22,608 |
Our PRQR Coverage
We haven't published any research on PRQR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PRQR Report →Similar Companies
IMMP-5.63%
Immutep Limited
$0.47
EDIT+5.28%
Editas Medicine, Inc.
$2.59
CAPR+5.33%
Capricor Therapeutics, Inc.
$28.36
ACHV+3.39%
Achieve Life Sciences, Inc.
$4.60
ALLO+0.26%
Allogene Therapeutics, Inc.
$1.90
ARCT+3.51%
Arcturus Therapeutics Holdings Inc.
$6.92
MREO+8.40%
Mereo BioPharma Group plc
$0.26
VNDA+3.17%
Vanda Pharmaceuticals Inc.
$6.18